Related Experiment Video

Updated: Mar 21, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Tirofiban-Induced Thrombocytopenia Occurring with Crohn's Disease

Toni Ibrahim1, Fady El Karak2, Assem Araji1

  • 1Department of Cardiology, Bekaa Hospital, Zahle, Lebanon.

Case Reports in Cardiology
|May 5, 2016
PubMed

Insights

This case report highlights a potential link between tirofiban-induced thrombocytopenia (TIT) and inflammatory bowel disease. Close platelet count monitoring is crucial for patients experiencing allergic reactions to tirofiban.

Area of Science:

  • Cardiology
  • Gastroenterology
  • Pharmacology

Background:

  • Severe refractory Crohn's disease poses complex management challenges.
  • Acute coronary syndrome necessitates urgent intervention, including angioplasty.
  • Tirofiban is an antiplatelet medication used in acute coronary syndromes.

Purpose of the Study:

  • To report a case of severe tirofiban-induced thrombocytopenia (TIT) in a patient with Crohn's disease.
  • To explore a potential association between TIT and inflammatory bowel disease.
  • To emphasize the importance of platelet count monitoring in specific patient populations.

Main Methods:

  • Case report of a 69-year-old male patient.
  • Detailed clinical presentation including Crohn's disease and acute coronary syndrome.
  • Observation of adverse drug reaction to tirofiban and its management.

Main Results:

  • The patient developed severe tirofiban-induced thrombocytopenia (TIT) following angioplasty.
  • A type I allergic reaction preceded the thrombocytopenia, requiring steroid and antihistamine treatment.
  • Thrombocytopenia resolved spontaneously within 48 hours without complications.

Conclusions:

  • A possible association between tirofiban-induced thrombocytopenia (TIT) and inflammatory bowel disease is suggested.
  • Strict platelet count monitoring is recommended for patients with inflammatory bowel disease who exhibit allergic reactions to tirofiban.
  • This case underscores the need for vigilance regarding drug-induced thrombocytopenia in patients with complex medical histories.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.4K
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

7.8K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
722
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
655
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
606
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.5K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
910
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K